

Updated (2023–2024 Formula) COVID-19 Vaccine

Interim 2023-2024 COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



The following tables provide COVID-19 vaccination schedules based on age, health status, and product. For detailed guidance see [Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC](#).

Table 1a. For people who are **NOT** moderately or severely immunocompromised*

2023-24 Moderna COVID-19 Vaccine Vaccine type: mRNA			
Age	COVID-19 Vaccination History [†] (regardless of COVID-19 vaccine formula)	2023-24 Vaccine Schedule	Administer
6 months through 4 years	Unvaccinated (0 doses)	Give a 2-dose initial series. Administer: <ul style="list-style-type: none"> • Dose 1 now • Dose 2 at least 4–8 weeks after Dose 1[‡] 	0.25 mL/25 μ g
	1 previous dose of any Moderna COVID-19 Vaccine (Dose 1) [§]	Give Dose 2 at least 4–8 weeks after the last dose [‡]	From a dark-blue capped vial with a green label
	2 or more previous doses of any Moderna COVID-19 vaccine, NOT including at least 1 dose of 2023–24 vaccine [¶]	Give 1 dose at least 8 weeks (2 months) after the last dose	Intramuscular (IM) injection
	2 or more previous doses of any Moderna COVID-19 vaccine, INCLUDING at least 1 dose of 2023–24 vaccine [¶]	No further doses are indicated	
5 through 11 years	Unvaccinated (0 doses)	Give 1 dose now	0.25 mL/25 μ g
	Any number of previous doses of COVID-19 vaccine, NOT including at least 1 dose of 2023–24 vaccine**	Give 1 dose at least 8 weeks (2 months) after the last dose	From a dark-blue capped vial with a green label
	Any number of previous doses of COVID-19 vaccine, INCLUDING at least 1 dose of 2023–24 vaccine**	No further doses are indicated	
12 years and older	Unvaccinated (0 doses)	Give 1 dose now	0.5 mL/50 μ g
	Any number of previous doses of COVID-19 vaccine, NOT including at least 1 dose of 2023–24 vaccine	Give 1 dose at least 8 weeks (2 months) after the last dose	
	Any number of previous doses of COVID-19 vaccine, INCLUDING at least 1 dose of 2023–24 vaccine ^{††}	<p>People 12 through 64 years of age: No further doses are indicated.</p> <p>People 65 years of age and older: Administer 1 additional dose at least 4 months following the last recommended dose of 2023–24 COVID-19 Vaccine.</p>	Intramuscular (IM) injection

* Persons with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

† COVID-19 vaccination history refers to previous receipt of dose(s) of Original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of the three, unless otherwise specified; for people ages 12 years and older, Original monovalent Novavax COVID-19 Vaccine doses, alone or in combination with any mRNA vaccine doses; and for people ages 18 years and older, Janssen COVID-19 Vaccine doses, alone or in combination with any mRNA or Original monovalent Novavax vaccine doses.

‡ An 8-week interval between the first and second doses of Moderna COVID-19 vaccine might be optimal for some people as it might reduce the small risk of myocarditis and pericarditis associated with this vaccine. See [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) for additional information.

§ People who are recommended to receive a multidose mRNA series for initial vaccination (e.g., children ages 6 months–4 years) should receive all doses from the same manufacturer. However, in the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered: same vaccine not available at the vaccination site at the time of the clinic visit; previous dose unknown; person would otherwise not receive a recommended vaccine dose; person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication

¶ For children who have received 1 Moderna and 1 Pfizer-BioNTech vaccine product of any formulation, follow a 3-dose schedule. A third dose of either Moderna vaccine or Pfizer-BioNTech vaccine should be administered at least 8 weeks after the second dose.

** For children who transition from age 4 years to age 5 years during the initial vaccination series: **Moderna series:** Children 6 months through 11 years are recommended to receive updated (2023–2024 Formula) Moderna COVID-19 Vaccine, 0.25 mL/25 μ g (dark blue cap; green label) for all doses, as per the [FDA EUA](#); there is no dosage change.

†† If the immunization history includes only 1 dose of updated 2023-24 Novavax COVID-19 vaccine, see [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) for detailed guidance.

Updated (2023–2024 Formula) COVID-19 Vaccine

Interim 2023–2024 COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 1b. For people who are **NOT** moderately or severely immunocompromised*

2023–24 Pfizer-BioNTech COVID-19 Vaccine Vaccine type: mRNA			
Age	COVID-19 Vaccination History [†] (regardless of COVID-19 vaccine formula)	2023–24 Vaccine Schedule	Administer
6 months through 4 years	Unvaccinated (0 doses)	Give a 3-dose initial series. Administer: <ul style="list-style-type: none"> • Dose 1 now • Dose 2 at least 3–8 weeks after Dose 1[‡] • Dose 3 at least 8 weeks (2 months) after Dose 2 	0.3 mL/3 µg From yellow-capped vial with yellow label Intramuscular (IM) injection
	1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1) [§]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 2 at least 3–8 weeks after Dose 1[‡] • Dose 3 at least 8 weeks (2 months) after Dose 2 	
	2 previous doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2) ^{§¶}	Complete series. Administer: <ul style="list-style-type: none"> • Dose 3 at least 8 weeks (2 months) after Dose 2 	
	3 or more previous doses of any Pfizer-BioNTech COVID-19 vaccine, NOT including at least 1 dose of 2023–24 COVID-19 vaccine ^{§¶¶}	Give 1 dose at least 8 weeks (2 months) after the last dose	
	3 or more previous doses of any Pfizer-BioNTech COVID-19 vaccine, INCLUDING at least 1 dose of 2023–24 COVID-19 vaccine ^{§¶¶}	No further doses are indicated	
5 through 11 years	Unvaccinated (0 doses)	Give 1 dose now	0.3 mL/10 µg From blue-capped vial with blue label Intramuscular (IM) injection
	Any number of previous doses of COVID-19 vaccine, NOT including at least 1 dose of 2023–24 COVID-19 vaccine ^{**}	Give 1 dose at least 8 weeks (2 months) after the last dose	
	Any number of previous doses of COVID-19 vaccine, INCLUDING at least 1 dose of 2023–24 COVID-19 vaccine ^{**}	No further doses are indicated	
12 years and older	Unvaccinated (0 doses)	Give 1 dose now	0.3 mL/30 µg From gray-capped vial with gray label or manufacturer-filled syringe with gray box on label Intramuscular (IM) injection
	Any number of previous doses of COVID-19 vaccine, NOT including at least 1 dose of 2023–24 COVID-19 vaccine	Give 1 dose at least 8 weeks (2 months) after the last dose	
	Any number of previous doses of COVID-19 vaccine, INCLUDING at least 1 dose of 2023–24 COVID-19 vaccine ^{††}	People 12 through 64 years of age: No further doses are indicated. People 65 years of age and older: Administer 1 additional dose at least 4 months following the last recommended dose of 2023–24 COVID-19 Vaccine.	

* Persons with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

† COVID-19 vaccination history refers to previous receipt of dose(s) of Original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of the three, unless otherwise specified; for people ages 12 years and older, Original monovalent Novavax COVID-19 Vaccine doses, alone or in combination with any mRNA vaccine doses; and for people ages 18 years and older, Janssen COVID-19 Vaccine doses, alone or in combination with any mRNA or Original monovalent Novavax vaccine doses.

‡ An 8-week interval between the first and second doses of Pfizer-BioNTech COVID-19 vaccine might be optimal for some people as it might reduce the small risk of myocarditis and pericarditis associated with this vaccine. See [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) for additional information.

§ People who are recommended to receive a multidose mRNA series for initial vaccination (e.g., children ages 6 months–4 years) should receive all doses from the same manufacturer. However, in the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered: same vaccine not available at the vaccination site at the time of the clinic visit; previous dose unknown; person would otherwise not receive a recommended vaccine dose; person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication

¶ For children who have received 1 Moderna and 1 Pfizer-BioNTech vaccine product of any formulation, follow a 3-dose schedule. A third dose of either Moderna vaccine or Pfizer-BioNTech vaccine should be administered at least 8 weeks after the second dose.

** For children who transition from age 4 years to age 5 years during the initial vaccination series: **Pfizer-BioNTech series:** Children are recommended to receive updated (2023–2024 Formula) Pfizer-BioNTech COVID-19 Vaccine, 0.3 mL/10 µg (blue cap; blue label) for all doses received on or after turning age 5 years. Alternatively, they may complete the 3-dose series with updated (2023–2024 Formula) Pfizer-BioNTech COVID-19 Vaccine for ages 6 months–4 years, 0.3 mL/3 µg (yellow cap; yellow label), as per the [FDA EUA](#).

†† If the immunization history includes only 1 dose of 2023–24 Novavax COVID-19 vaccine, see [Interim Clinical Considerations for COVID-19 Vaccines](#) for detailed guidance.

Updated (2023–2024 Formula) COVID-19 Vaccine

Interim 2023-2024 COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 1c. For people who are **NOT** moderately or severely immunocompromised*

2023-24 Novavax COVID-19 Vaccine Vaccine type: Protein subunit			
Age	COVID-19 Vaccination History [†]	2023-24 Vaccine Schedule	Administer
12 years and older	Unvaccinated (0 doses)	Give a 2-dose initial series. Administer: <ul style="list-style-type: none"> • Dose 1 now • Dose 2 at least 3–8 weeks after Dose 1[‡] 	0.5 mL/5 μ g rS protein and 50 μ g Matrix-M adjuvant From a blue-capped vial with a blue label Intramuscular (IM) injection
	1 previous dose of 2023-24 Novavax COVID-19 Vaccine (Dose 1)	Give Dose 2 at least 3–8 weeks after the last dose [‡]	
	Any number of previous doses of COVID-19 vaccine, NOT including at least 1 dose of 2023–24 vaccine	Give 1 dose at least 8 weeks (2 months) after the last dose	
	Any number of previous doses of COVID-19 vaccine, WITH at least 1 dose of 2023–24 vaccine	<p>People 12 through 64 years of age: No further doses are indicated.</p> <p>People 65 years of age and older: Administer 1 additional dose at least 4 months following the last recommended dose of 2023–24 COVID-19 Vaccine.</p>	

* Persons with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

[†] COVID-19 vaccination history refers to previous receipt of dose(s) of Original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of the three, unless otherwise specified; for people ages 12 years and older, Original monovalent Novavax COVID-19 Vaccine doses, alone or in combination with any mRNA vaccine doses; and for people ages 18 years and older, Janssen COVID-19 Vaccine doses, alone or in combination with any mRNA or Original monovalent Novavax vaccine doses.

[‡] An 8-week interval between the first and second doses of Novavax COVID-19 vaccine might be optimal for some people as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines. See [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) for additional information.

Updated (2023–2024 Formula) COVID-19 Vaccine

Interim 2023-2024 COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 2a. For people who **ARE** moderately or severely immunocompromised

2023-24 Moderna COVID-19 Vaccine Vaccine type: mRNA			
Age	COVID-19 Vaccination History* (regardless of COVID-19 vaccine formula)	2023-24 Vaccine Schedule	Administer
6 months through 11 years	Unvaccinated (0 doses)	Give a 3-dose initial series. Administer: <ul style="list-style-type: none"> • Dose 1 now • Dose 2 at least 4 weeks after Dose 1 • Dose 3 at least 4 weeks after Dose 2 	0.25 mL/25 µg
	1 previous dose of any Moderna COVID-19 Vaccine (Dose 1) [†]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 2 at least 4 weeks after Dose 1 • Dose 3 at least 4 weeks after Dose 2 	
	2 previous doses of any Moderna COVID-19 Vaccine (Doses 1 and 2) [†]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 3 at least 4 weeks after Dose 2 	From a single-dose, dark-blue capped vial with a green label
	3 or more previous doses of Moderna COVID-19 Vaccine, NOT including at least 1 dose of 2023–24 COVID-19 vaccine [†]	Give 1 dose at least 8 weeks (2 months) after the last dose	Intramuscular (IM) injection
	3 or more previous doses of Moderna COVID-19 Vaccine, INCLUDING at least 1 dose of 2023–24 COVID-19 vaccine [†]	<ul style="list-style-type: none"> • These children may receive 1 additional dose at least 8 weeks (2 months) following the last recommended dose. • Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. • Any further additional doses should be administered at least 8 weeks (2 months) after the last COVID-19 vaccine dose. 	

* COVID-19 vaccination history refers to previous receipt of dose(s) of Original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of the three, unless otherwise specified; for people ages 12 years and older, Original monovalent Novavax COVID-19 Vaccine doses, alone or in combination with any mRNA vaccine doses; and for people ages 18 years and older, Janssen COVID-19 Vaccine doses, alone or in combination with any mRNA or Original monovalent Novavax vaccine doses.

[†] People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., people who are moderately or severely immunocompromised) should receive all doses from the same manufacturer. However, in the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered: same vaccine not available at the vaccination site at the time of the clinic visit; previous dose unknown; person would otherwise not receive a recommended vaccine dose; person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication.

Updated (2023–2024 Formula) COVID-19 Vaccine

Interim 2023-2024 COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 2a. For people who **ARE** moderately or severely immunocompromised *Continued*

2023-24 Moderna COVID-19 Vaccine - CONTINUED Vaccine type: mRNA			
Age	COVID-19 Vaccination History* (regardless of COVID-19 vaccine formula)	2023-24 Vaccine Schedule	Administer
12 years and older	Unvaccinated 0 doses	Give a 3-dose initial series. Administer: <ul style="list-style-type: none"> • Dose 1 now • Dose 2 at least 4 weeks after Dose 1 • Dose 3 at least 4 weeks after Dose 2 	0.5 mL/50 µg From a dark-blue capped vial with a blue label Intramuscular (IM) injection
	1 previous dose of any Moderna COVID-19 Vaccine (Dose 1) [†]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 2 at least 4 weeks after Dose 1 • Dose 3 at least 4 weeks after Dose 2 	
	2 previous doses of any Moderna COVID-19 Vaccine (Doses 1 and 2) [†]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 3 at least 4 weeks after Dose 2 	
	3 or more previous doses of Moderna COVID-19 Vaccine, NOT including at least 1 dose of 2023–24 COVID-19 vaccine [†]	Give 1 dose at least 8 weeks (2 months) after the last dose	
	3 or more previous doses of Moderna COVID-19 Vaccine, INCLUDING at least 1 dose of 2023–24 COVID-19 vaccine [†]	<p>People 12 through 64 years of age may receive 1 additional dose at least 8 weeks (2 months) following the last recommended dose.</p> <ul style="list-style-type: none"> • Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. • Any further additional doses should be administered at least 8 weeks (2 months) after the last COVID-19 vaccine dose. <p>People 65 years of age and older administer 1 additional dose at least 8 weeks (2 months) following the last recommended dose of 2023–24 COVID-19 Vaccine.</p> <ul style="list-style-type: none"> • Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. • Any further additional doses should be administered at least 8 weeks (2 months) after the last COVID-19 vaccine dose. 	

* COVID-19 vaccination history refers to previous receipt of dose(s) of Original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of the three, unless otherwise specified; for people ages 12 years and older, Original monovalent Novavax COVID-19 Vaccine doses, alone or in combination with any mRNA vaccine doses; and for people ages 18 years and older, Janssen COVID-19 Vaccine doses, alone or in combination with any mRNA or Original monovalent Novavax vaccine doses.

† People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., people who are moderately or severely immunocompromised) should receive all doses from the same manufacturer. However, in the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered: same vaccine not available at the vaccination site at the time of the clinic visit; previous dose unknown; person would otherwise not receive a recommended vaccine dose; person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication.

Updated (2023–2024 Formula) COVID-19 Vaccine

Interim 2023–2024 COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 2b. For people who **ARE** moderately or severely immunocompromised

2023–24 Pfizer-BioNTech COVID-19 Vaccine Vaccine type: mRNA			
Age	COVID-19 Vaccination History* (regardless of COVID-19 vaccine formula)	2023–24 Vaccine Schedule	Administer
6 months through 4 years	Unvaccinated (0 doses)	Give a 3-dose initial series. Administer: <ul style="list-style-type: none"> • Dose 1 now • Dose 2 at least 3 weeks after Dose 1 • Dose 3 at least 8 weeks (2 months) after Dose 2 	0.3 mL/3 μ g From yellow-capped vial with yellow label Intramuscular (IM) injection
	1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1) [†]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 2 at least 3 weeks after Dose 1 • Dose 3 at least 8 weeks (2 months) after Dose 2 	
	2 previous doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2) [†]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 3 at least 8 weeks (2 months) after Dose 2 	
	3 or more previous doses of Pfizer-BioNTech COVID-19 Vaccine, NOT including at least 1 dose of 2023–24 COVID-19 vaccine [†]	Give 1 dose at least 8 weeks (2 months) after the last dose	
	3 or more previous doses of Pfizer-BioNTech COVID-19 Vaccine, INCLUDING at least 1 dose of 2023–24 COVID-19 vaccine [†]	<ul style="list-style-type: none"> • These children may receive 1 additional dose at least 8 weeks (2 months) following the last recommended dose. • Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. • Any further additional doses should be administered at least 8 weeks (2 months) after the last COVID-19 vaccine dose. 	
5 through 11 years	Unvaccinated (0 doses)	Give a 3-dose initial series. Administer: <ul style="list-style-type: none"> • Dose 1 now • Dose 2 at least 3 weeks after Dose 1 • Dose 3 at least 4 weeks after Dose 2 	0.3 mL/10 μ g From blue-capped vial with blue label Intramuscular (IM) injection
	1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1) [†]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 2 at least 3 weeks after Dose 1 • Dose 3 at least 4 weeks after Dose 2 	
	2 previous doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2) [†]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 3 at least 4 weeks after Dose 2 	
	3 or more previous doses of Pfizer-BioNTech COVID-19 Vaccine, NOT including at least 1 dose of 2023–24 COVID-19 vaccine [†]	Give 1 dose at least 8 weeks (2 months) after the last dose	
	3 or more previous doses of Pfizer-BioNTech COVID-19 Vaccine, INCLUDING at least 1 dose of 2023–24 COVID-19 vaccine [†]	<ul style="list-style-type: none"> • These children may receive 1 additional dose at least 8 weeks (2 months) following the last recommended dose. • Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. • Any further additional doses should be administered at least 8 weeks (2 months) after the last COVID-19 vaccine dose. 	

* COVID-19 vaccination history refers to previous receipt of dose(s) of Original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of the three, unless otherwise specified; for people ages 12 years and older, Original monovalent Novavax COVID-19 Vaccine doses, alone or in combination with any mRNA vaccine doses; and for people ages 18 years and older, Janssen COVID-19 Vaccine doses, alone or in combination with any mRNA or Original monovalent Novavax vaccine doses.

[†] People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., people who are moderately or severely immunocompromised) should receive all doses from the same manufacturer. However, in the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered: same vaccine not available at the vaccination site at the time of the clinic visit; previous dose unknown; person would otherwise not receive a recommended vaccine dose; person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication.

Updated (2023–2024 Formula) COVID-19 Vaccine

Interim 2023-2024 COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 2b. For people who **ARE** moderately or severely immunocompromised *Continued*

2023-24 Pfizer-BioNTech COVID-19 Vaccine - CONTINUED Vaccine type: mRNA			
Age	COVID-19 Vaccination History* (regardless of COVID-19 vaccine formula)	2023-24 Vaccine Schedule	Administer
12 years and older	Unvaccinated 0 doses	Give a 3-dose initial series. Administer: <ul style="list-style-type: none"> • Dose 1 now • Dose 2 at least 3 weeks after Dose 1 • Dose 3 at least 4 weeks after Dose2 	0.3 mL/30 µg From gray-capped vial with gray label or manufacturer-filled syringe with gray box on label Intramuscular (IM) injection
	1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1) [†]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 2 at least 3 weeks after Dose 1 • Dose 3 at least 4 weeks after Dose2 	
	2 previous doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2) [†]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 3 at least 4 weeks after Dose2 	
	3 or more previous doses of Pfizer-BioNTech COVID-19 Vaccine, NOT including at least 1 dose of 2023–24 COVID-19 vaccine [†]	Give 1 dose at least 8 weeks (2 months) after the last dose	
	3 or more previous doses of Pfizer-BioNTech COVID-19 Vaccine, INCLUDING at least 1 dose of 2023–24 COVID-19 vaccine [†]	<p>People 12 through 64 years of age may receive 1 additional dose at least 8 weeks (2 months) following the last recommended dose.</p> <ul style="list-style-type: none"> • Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. • Any further additional doses should be administered at least 8 weeks (2 months) after the last COVID-19 vaccine dose. <p>People 65 years of age and older: Administer 1 additional dose at least 8 weeks (2 months) following the last recommended dose of 2023–24 COVID-19 Vaccine.</p> <ul style="list-style-type: none"> • Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. • Any further additional doses should be administered at least 8 weeks (2 months) after the last COVID-19 vaccine dose. 	

* COVID-19 vaccination history refers to previous receipt of dose(s) of Original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of the three, unless otherwise specified; for people ages 12 years and older, Original monovalent Novavax COVID-19 Vaccine doses, alone or in combination with any mRNA vaccine doses; and for people ages 18 years and older, Janssen COVID-19 Vaccine doses, alone or in combination with any mRNA or Original monovalent Novavax vaccine doses.

† People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., people who are moderately or severely immunocompromised) should receive all doses from the same manufacturer. However, in the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered: same vaccine not available at the vaccination site at the time of the clinic visit; previous dose unknown; person would otherwise not receive a recommended vaccine dose; person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication.

Updated (2023–2024 Formula) COVID-19 Vaccine

Interim 2023–2024 COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 2c. For people who **ARE** moderately or severely immunocompromised

2023–24 Novavax COVID-19 Vaccine Vaccine type: Protein subunit			
Age	COVID-19 Vaccination History*	2023–24 Vaccine Schedule	Administer
12 years and older	Unvaccinated (0 doses)	Give a 2-dose initial series. Administer: <ul style="list-style-type: none"> • Dose 1 now • Dose 2 at least 3 weeks after Dose 1 	0.5 mL/5 μ g rS protein and 50 μ g Matrix-M adjuvant From a blue-capped vial with a blue label Intramuscular (IM) injection
	1 previous dose of 2023–24 Novavax COVID-19 Vaccine (Dose 1) [†]	Give Dose 2 at least 3 weeks after the last dose	
	1 or more previous doses of any COVID-19 vaccine, NOT including at least 1 dose of 2023–24 vaccine [†]	Give 1 dose at least 8 weeks (2 months) after the last dose	
	2 or more previous doses of any COVID-19 vaccine, INCLUDING at least 1 dose of 2023–24 vaccine [†]	<p>People 12 through 64 years of age may receive 1 additional dose at least 8 weeks (2 months) following the last recommended dose.</p> <ul style="list-style-type: none"> • Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. • Any further additional doses should be administered at least 8 weeks (2 months) after the last COVID-19 vaccine dose. <p>People 65 years of age and older: Administer 1 additional dose at least 8 weeks (2 months) following the last recommended dose of 2023–24 COVID-19 Vaccine.</p> <ul style="list-style-type: none"> • Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. • Any further additional doses should be administered at least 8 weeks (2 months) after the last COVID-19 vaccine dose. 	

* COVID-19 vaccination history refers to previous receipt of dose(s) of Original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of the three, unless otherwise specified; for people ages 12 years and older, Original monovalent Novavax COVID-19 Vaccine doses, alone or in combination with any mRNA vaccine doses; and for people ages 18 years and older, Janssen COVID-19 Vaccine doses, alone or in combination with any mRNA or Original monovalent Novavax vaccine doses.

[†] People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., people who are moderately or severely immunocompromised) should receive all doses from the same manufacturer. However, in the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered: same vaccine not available at the vaccination site at the time of the clinic visit; previous dose unknown; person would otherwise not receive a recommended vaccine dose; person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication.